Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Sorrento Therapeutics, Inc. | d826599dex312.htm |
| EX-32.1 - EX-32.1 - Sorrento Therapeutics, Inc. | d826599dex321.htm |
| EX-10.2 - EX-10.2 - Sorrento Therapeutics, Inc. | d826599dex102.htm |
| EX-31.1 - EX-31.1 - Sorrento Therapeutics, Inc. | d826599dex311.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q/A
(Amendment No. 1)
| x | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended September 30, 2014
OR
| ¨ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 001-36150
SORRENTO THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
| Delaware | 33-0344842 | |
| (State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification Number) |
6042 Cornerstone Ct. West,
Suite B
San Diego, California 92121
(Address of Principal Executive Offices)
(858) 210-3700
(Registrant’s Telephone Number, Including Area Code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨.
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated file or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
| Large accelerated filer | ¨ | Accelerated filer | ¨ | |||
| Non-accelerated filer | ¨ (Do not check if a smaller reporting company) | Smaller reporting company | x | |||
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x.
The number of shares of the issuer’s common stock, par value $0.0001 per share, outstanding as of October 29, 2014 was 28,932,850.
EXPLANATORY NOTE
Sorrento Therapeutics, Inc. (the “Company”) is filing this Amendment No. 1 (the “Amendment No. 1”) to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, which was originally filed on November 4, 2014 (the “Original Filing”) for the sole purpose of filing a revised copy of Exhibit 10.2 to the Form 10-Q reflecting a comment from the Securities and Exchange Commission in connection with the Company’s application for confidential treatment of such exhibit.
Other than the addition of Exhibit 10.2 no other changes have been made to the Original Filing.
This Amendment No. 1 does not reflect events that may have occurred subsequent to the filing date of the Original Filing, and does not modify or update in any way disclosures made in the Form 10-Q for the quarter ended September 30, 2014.
2
PART II. OTHER INFORMATION
| Item 6. | Exhibits. |
| 10.2* | Exclusive License and Development Agreement between Sorrento Therapeutics, Inc. and China Oncology Focus Limited dated October 3, 2014. | |
| 31.1 | Certification of Henry Ji, Ph.D., Principal Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended. | |
| 31.2 | Certification of Richard G. Vincent, Principal Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as amended. | |
| 32.1 | Certification of Henry Ji, Ph.D., Principal Executive Officer, and Richard G. Vincent, Principal Financial Officer, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, as amended. | |
| 101.INS** | XBRL Instance Document | |
| 101.SCH** | XBRL Taxonomy Extension Schema Document | |
| 101.CAL** | XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF** | XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB** | XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE** | XBRL Taxonomy Extension Presentation Linkbase Document | |
| * | Portions of this exhibit were omitted and filed separately with the U.S. Securities and Exchange Commission pursuant to a request for confidential treatment. |
| ** | Previously filed |
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| Sorrento Therapeutics, Inc. | ||||
| Date: November 25, 2014 | By: | /s/ Henry Ji, PH.D. | ||
| Henry Ji, Ph.D. | ||||
| Director, Chief Executive Officer & President | ||||
| (Principal Executive Officer) | ||||
| Date: November 25, 2014 | By: | /s/ Richard G. Vincent | ||
| Richard G. Vincent | ||||
| Chief Financial Officer | ||||
| (Principal Financial and Accounting Officer) | ||||
4